Further, there is growing evidence for a major role of HGF/SF and MET in the maintenance of cancer stem cells in colon17, breast18 and prostate19 carcinomas, and accumulating reports of involvement of the MET-HGF/SF axis in cancer cell resistance to targeted therapies both in vitro20–23 and in cancer patients24–26. Here, MET is linked to carcinoma.